CEFPODOXIME (BioDeep_00001868454)

Main id: BioDeep_00000006664

 


代谢物信息卡片


CEFPODOXIME

化学式: C15H17N5O6S2 (427.062)
中文名称: 头孢泊肟
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: COCC1=C(N2C(C(C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O
InChI: InChI=1S/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1

描述信息

A third-generation cephalosporin antibiotic with methoxymethyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamino substituents at positions 3 and 7, respectively, of the cephem skeleton. Given by mouth as its proxetil ester prodrug, it is used to treat acute otitis media, pharyngitis, and sinusitis.
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DD - Third-generation cephalosporins
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic

同义名列表

2 个代谢物同义名

CEFPODOXIME; Cefpodoxime



数据库引用编号

11 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 8 DCAF12, MEFV, MRTFA, NR3C1, PGM1, PGM2, RPL22, RPL4
Peripheral membrane protein 2 AP1S2, CYP27A1
Mitochondrion membrane 1 CYP27A1
Cytoplasmic vesicle, autophagosome 1 MEFV
Nucleus 8 DCAF12, MEFV, MRTFA, NR3C1, OMP, RPL22, RPL4, UNG
autophagosome 1 MEFV
cytosol 12 AP1S2, DCAF12, GPT, LACTB, MEFV, MRTFA, NR3C1, OMP, PGM1, PGM2, RPL22, RPL4
centrosome 2 DCAF12, NR3C1
nucleoplasm 4 MEFV, MRTFA, NR3C1, UNG
Cytoplasmic side 1 AP1S2
lamellipodium 1 MEFV
Multi-pass membrane protein 1 CACNA1I
Synapse 2 NR3C1, OMP
cell surface 1 TNR
glutamatergic synapse 3 MRTFA, RPL22, TNR
Golgi apparatus 1 AP1S2
Golgi membrane 1 AP1S2
lysosomal membrane 1 AP1S2
mitochondrial inner membrane 2 CYP27A1, TDH
neuronal cell body 1 OMP
postsynapse 1 MRTFA
Cytoplasm, cytosol 1 PGM2
Presynapse 2 MRTFA, RPL22
plasma membrane 1 CACNA1I
Membrane 3 CACNA1I, NR3C1, RPL4
axon 1 OMP
extracellular exosome 5 GPT, PGM1, PGM2, RPL22, RPL4
extracellular space 2 CGA, TNR
Schaffer collateral - CA1 synapse 1 TNR
mitochondrion 5 CYP27A1, LACTB, NR3C1, TDH, UNG
protein-containing complex 1 NR3C1
intracellular membrane-bounded organelle 1 AP1S2
Secreted 2 CGA, HTRA3
extracellular region 5 CGA, HTRA3, PGM1, PGM2, TNR
mitochondrial matrix 2 CYP27A1, NR3C1
Cytoplasm, cytoskeleton, microtubule organizing center, centrosome 2 DCAF12, NR3C1
Secreted, extracellular space, extracellular matrix 1 TNR
cytoplasmic vesicle 1 MEFV
nucleolus 1 RPL4
Early endosome 1 AP1S2
Membrane, clathrin-coated pit 1 AP1S2
clathrin-coated pit 1 AP1S2
Cell projection, lamellipodium 1 MEFV
Mitochondrion inner membrane 1 CYP27A1
Membrane raft 1 TNR
Cytoplasm, cytoskeleton, spindle 1 NR3C1
focal adhesion 2 RPL22, RPL4
microtubule 1 MEFV
spindle 1 NR3C1
collagen-containing extracellular matrix 1 TNR
nuclear speck 1 NR3C1
Cell projection, ruffle 1 MEFV
ruffle 1 MEFV
chromatin 1 NR3C1
microtubule associated complex 1 MEFV
Chromosome 1 NR3C1
Endomembrane system 1 AP1S2
Cytoplasmic vesicle membrane 1 AP1S2
Nucleus, nucleoplasm 1 NR3C1
trans-Golgi network membrane 1 AP1S2
ficolin-1-rich granule lumen 2 PGM1, PGM2
secretory granule lumen 1 PGM2
Golgi lumen 1 CGA
voltage-gated calcium channel complex 1 CACNA1I
tertiary granule lumen 1 PGM1
perineuronal net 1 TNR
ribonucleoprotein complex 2 RPL22, RPL4
[Isoform 2]: Nucleus 1 MEFV
[Isoform 1]: Cytoplasm, cytoskeleton 1 MEFV
canonical inflammasome complex 1 MEFV
AP-type membrane coat adaptor complex 1 AP1S2
membrane coat 1 AP1S2
Rough endoplasmic reticulum 1 RPL4
AP-1 adaptor complex 1 AP1S2
cytosolic ribosome 2 RPL22, RPL4
[Isoform Alpha]: Cytoplasm 1 NR3C1
ribosome 2 RPL22, RPL4
follicle-stimulating hormone complex 1 CGA
pituitary gonadotropin complex 1 CGA
[Isoform Beta]: Nucleus 1 NR3C1
[Isoform Alpha-B]: Nucleus 1 NR3C1
cytosolic large ribosomal subunit 2 RPL22, RPL4
tenascin complex 1 TNR
Cul4-RING E3 ubiquitin ligase complex 1 DCAF12


文献列表

  • André Birgy, Fouad Madhi, Camille Jung, Corinne Levy, Aurélie Cointe, Philippe Bidet, Claire Amaris Hobson, Stéphane Bechet, Elsa Sobral, Hoang Vuthien, Agnès Ferroni, Saïd Aberrane, Gaëlle Cuzon, Laetitia Beraud, Vincent Gajdos, Elise Launay, Didier Pinquier, Hervé Haas, Marie Desmarest, Marie-Aliette Dommergues, Robert Cohen, Stéphane Bonacorsi. Clavulanate combinations with mecillinam, cefixime or cefpodoxime against ESBL-producing Enterobacterales frequently associated with blaOXA-1 in a paediatric population with febrile urinary tract infections. The Journal of antimicrobial chemotherapy. 2021 10; 76(11):2839-2846. doi: 10.1093/jac/dkab289. [PMID: 34453533]
  • Ozlem Guneysel, Enes Suman, Tuba Cimilli Ozturk. TRIMETHOPRIM-SULFAMETHOXAZOLE RESISTANCE AND FOSFOMYCIN SUSCEPTIBILITY RATES IN UNCOMPLICATED URINARY TRACT INFECTIONS: TIME TO CHANGE THE ANTIMICROBIAL PREFERENCES. Acta clinica Croatica. 2016 Mar; 55(1):49-57. doi: 10.20471/acc.2016.55.01.8. [PMID: 27333718]
  • Beth Blane, Hayley J Brodrick, Theodore Gouliouris, Kirsty E Ambridge, Angela D Kidney, Catherine M Ludden, Direk Limmathurotsakul, M Estée Török, Sharon J Peacock. Comparison of 2 chromogenic media for the detection of extended-spectrum β-lactamase producing Enterobacteriaceae stool carriage in nursing home residents. Diagnostic microbiology and infectious disease. 2016 Mar; 84(3):181-3. doi: 10.1016/j.diagmicrobio.2015.11.008. [PMID: 26712266]
  • David A Bookstaver, Christopher M Bland, Miguel A Arroyo. Evaluation of cefazolin as a surrogate marker for cefpodoxime susceptibility for urinary tract isolates. Journal of medical microbiology. 2015 Oct; 64(10):1170-1173. doi: 10.1099/jmm.0.000142. [PMID: 26219948]
  • J A Lewis, P C L Moore, D L Arnold, L M Lawrance. Chromosomal ampC mutations in cefpodoxime-resistant, ESBL-negative uropathogenic Escherichia coli. British journal of biomedical science. 2015; 72(1):7-11. doi: 10.1080/09674845.2015.11666789. [PMID: 25906485]
  • Bruce D Erickson, Christopher A Elkins, Lisa B Mullis, Thomas M Heinze, R Doug Wagner, Carl E Cerniglia. A metallo-β-lactamase is responsible for the degradation of ceftiofur by the bovine intestinal bacterium Bacillus cereus P41. Veterinary microbiology. 2014 Aug; 172(3-4):499-504. doi: 10.1016/j.vetmic.2014.05.032. [PMID: 24972871]
  • J-h Zhang, S Guo, M Xu, L-X Wu. A simply HPLC method for determination of cefpodoxime in Chinese volunteer and pharmacokinetic study. Drug research. 2013 Aug; 63(8):435-8. doi: 10.1055/s-0033-1345149. [PMID: 23677701]
  • Niveen A Mohamed, Hanaa M Abdel-Wadood, Sameh Ahmed. An efficient one-pot reaction for selective fluorimetric determination of cefpodoxime and its prodrug. Talanta. 2011 Sep; 85(4):2121-7. doi: 10.1016/j.talanta.2011.07.053. [PMID: 21872067]
  • V Kumar, R Madabushi, M B B Lucchesi, H Derendorf. Pharmacokinetics of cefpodoxime in plasma and subcutaneous fluid following oral administration of cefpodoxime proxetil in male beagle dogs. Journal of veterinary pharmacology and therapeutics. 2011 Apr; 34(2):130-5. doi: 10.1111/j.1365-2885.2010.01198.x. [PMID: 21395603]
  • April Barbour, Stephan Schmidt, Sreedharan Nair Sabarinath, Maria Grant, Christoph Seubert, Donna Skee, Bindu Murthy, Hartmut Derendorf. Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis. Antimicrobial agents and chemotherapy. 2009 Jul; 53(7):2773-6. doi: 10.1128/aac.01409-08. [PMID: 19364847]
  • R Sharma, R P D Cooke, J G Ratcliffe. Detection of ESBL bacteria from clinical specimens: evaluation of a new selective medium. British journal of biomedical science. 2008; 65(4):191-4. doi: 10.1080/09674845.2008.11732827. [PMID: 19181037]
  • S A Brown, J F Boucher, V L Hubbard, M J Prough, T F Flook. The comparative plasma pharmacokinetics of intravenous cefpodoxime sodium and oral cefpodoxime proxetil in beagle dogs. Journal of veterinary pharmacology and therapeutics. 2007 Aug; 30(4):320-6. doi: 10.1111/j.1365-2885.2007.00873.x. [PMID: 17610405]
  • O Echeverria, L Alou, D Sevillano, N Gonzalez, M L Gomez-Lus, L Aguilar, J Prieto. Pharmacodynamics of simulated total versus free-drug serum concentrations of a low versus a high protein bound third-generation oral cephalosporin (Cefpodoxime versus cefditoren) against Streptococcus pneumoniae. Journal of chemotherapy (Florence, Italy). 2007 Jun; 19(3):288-94. doi: 10.1179/joc.2007.19.3.288. [PMID: 17594924]
  • Tetsuro Muratani, Tetsuro Matsumoto. Urinary tract infection caused by fluoroquinolone- and cephem-resistant Enterobacteriaceae. International journal of antimicrobial agents. 2006 Aug; 28 Suppl 1(?):S10-3. doi: 10.1016/j.ijantimicag.2006.05.009. [PMID: 16829056]
  • Kenichi Kaneko, Yoshinori Sato, Shu-ko Tokunaga, Sho-ko Tamaki, Ryoichi Okamoto, Matsuhisa Inoue. AmpC beta-lactamase-mediated cefpodoxime-resistant Escherichia coli isolated from faecal samples of healthy volunteers. The Journal of antimicrobial chemotherapy. 2006 Feb; 57(2):369-71. doi: 10.1093/jac/dki438. [PMID: 16338950]
  • Ping Liu, Richard Fuhrherr, Alistair I Webb, Bernd Obermann, Hartmut Derendorf. Tissue penetration of cefpodoxime into the skeletal muscle and lung in rats. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2005 Jul; 25(4-5):439-44. doi: 10.1016/j.ejps.2005.04.012. [PMID: 15905079]
  • Ping Liu, Markus Müller, Maria Grant, Bernd Obermann, Hartmut Derendorf. Tissue penetration of cefpodoxime and cefixime in healthy subjects. Journal of clinical pharmacology. 2005 May; 45(5):564-9. doi: 10.1177/0091270004273679. [PMID: 15831780]
  • Ping Liu, Markus Müller, Maria Grant, Alistair I Webb, Bernd Obermann, Hartmut Derendorf. Interstitial tissue concentrations of cefpodoxime. The Journal of antimicrobial chemotherapy. 2002 Jul; 50 Suppl(?):19-22. doi: 10.1093/jac/dkf804. [PMID: 12077156]
  • G E Stein, S Schooley, R D Walker, L Strenkoski-Nix. Pharmacodynamic activity of five oral cephalosporins against Haemophilus influenzae. Pharmacotherapy. 1997 Mar; 17(2):235-41. doi: NULL. [PMID: 9085313]
  • T N Bairamis, T P Nikolopoulos, D A Kafetzis, P Begue, B Lenfant, D C Kandiloros, N J Apostolopoulos. Concentrations of cefpodoxime in plasma, adenoid, and tonsillar tissue after repeated administrations of cefpodoxime proxetil in children. The Journal of antimicrobial chemotherapy. 1996 Apr; 37(4):821-4. doi: 10.1093/jac/37.4.821. [PMID: 8722549]
  • M T Borin, K K Forbes, G S Hughes. The bioavailability of cefpodoxime proxetil tablets relative to an oral solution. Biopharmaceutics & drug disposition. 1995 May; 16(4):295-302. doi: 10.1002/bdd.2510160405. [PMID: 7548778]
  • P J Baker, W F Busby, M E Wilson. Subinhibitory concentrations of cefpodoxime alter membrane protein expression of Actinobacillus actinomycetemcomitans and enhance its susceptibility to killing by neutrophils. Antimicrobial agents and chemotherapy. 1995 Feb; 39(2):406-12. doi: 10.1128/aac.39.2.406. [PMID: 7726506]
  • F Camus, A Deslandes, L Harcouet, R Farinotti. High-performance liquid chromatographic method for the determination of cefpodoxime levels in plasma and sinus mucosa. Journal of chromatography. B, Biomedical applications. 1994 Jun; 656(2):383-8. doi: 10.1016/0378-4347(94)00122-7. [PMID: 7987491]
  • M J Lovdahl, K E Reher, H Q Russlie, D M Canafax. Determination of cefpodoxime levels in chinchilla middle ear fluid and plasma by high-performance liquid chromatography. Journal of chromatography. B, Biomedical applications. 1994 Mar; 653(2):227-32. doi: 10.1016/0378-4347(93)e0420-u. [PMID: 8205250]
  • S Valentini, G Coratza, G M Rossolini, O Massidda, G Satta. In-vitro evaluation of cefpodoxime. The Journal of antimicrobial chemotherapy. 1994 Mar; 33(3):495-508. doi: 10.1093/jac/33.3.495. [PMID: 8040114]
  • J M Casellas, G Tome, R Exeni, I Grimoldi, M Goldberg, A E Farinati. Serum and urinary cefpodoxime levels and time killing curves performed in the urine of children presenting urinary tract infections. Pathologie-biologie. 1993 Apr; 41(4):385-91. doi: NULL. [PMID: 8233640]
  • D R Baldwin, R Wise, J M Andrews, D Honeybourne. Concentrations of cefpodoxime in serum and bronchial mucosal biopsies. The Journal of antimicrobial chemotherapy. 1992 Jul; 30(1):67-71. doi: 10.1093/jac/30.1.67. [PMID: 1429338]
  • M T Borin, G S Hughes, R K Patel, M E Royer, K S Cathcart. Pharmacokinetic and tolerance studies of cefpodoxime after single- and multiple-dose oral administration of cefpodoxime proxetil. Journal of clinical pharmacology. 1991 Dec; 31(12):1137-45. doi: 10.1002/j.1552-4604.1991.tb03686.x. [PMID: 1761737]
  • S Schubert, U Ullmann. Influence of cefpodoxime on selected immunological functions and bacterial pathogenicity factors in vitro. Zentralblatt fur Bakteriologie : international journal of medical microbiology. 1991 Jun; 275(2):233-40. doi: 10.1016/s0934-8840(11)80070-8. [PMID: 1930575]
  • F Molina, F Jehl, C Gallion, F Penner, H Monteil. Determination of the third generation oral cephalosporin cefpodoxime in biological fluids by high-speed high-performance liquid chromatography. Journal of chromatography. 1991 Jan; 563(1):205-10. doi: 10.1016/0378-4347(91)80297-p. [PMID: 2061390]
  • R Dumont, F Guetat, J M Andrews, E Sultan, B Lenfant. Concentrations of cefpodoxime in plasma and pleural fluid after a single oral dose of cefpodoxime proxetil. The Journal of antimicrobial chemotherapy. 1990 Dec; 26 Suppl E(?):41-6. doi: 10.1093/jac/26.suppl_e.41. [PMID: 2292529]
  • P Gehanno, J M Andrews, F Ichou, E Sultan, B Lenfant. Concentrations of cefpodoxime in plasma and tonsillar tissue after a single oral dose of cefpodoxime proxetil. The Journal of antimicrobial chemotherapy. 1990 Dec; 26 Suppl E(?):47-51. doi: 10.1093/jac/26.suppl_e.47. [PMID: 2292530]
  • L Couraud, J M Andrews, H Lecoeur, E Sultan, B Lenfant. Concentrations of cefpodoxime in plasma and lung tissue after a single oral dose of cefpodoxime proxetil. The Journal of antimicrobial chemotherapy. 1990 Dec; 26 Suppl E(?):35-40. doi: 10.1093/jac/26.suppl_e.35. [PMID: 2292528]
  • D Tremblay, A Dupront, C Ho, D Coussediere, B Lenfant. Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses. The Journal of antimicrobial chemotherapy. 1990 Dec; 26 Suppl E(?):21-8. doi: 10.1093/jac/26.suppl_e.21. [PMID: 2292526]
  • M T Borin, G S Hughes, C R Spillers, R K Patel. Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil. Antimicrobial agents and chemotherapy. 1990 Jun; 34(6):1094-9. doi: 10.1128/aac.34.6.1094. [PMID: 2393268]
  • R Wise, J M Andrews, J P Ashby, D Thornber. The in-vitro activity of cefpodoxime: a comparison with other oral cephalosporins. The Journal of antimicrobial chemotherapy. 1990 Apr; 25(4):541-50. doi: 10.1093/jac/25.4.541. [PMID: 2351624]
  • P O'Neill, K Nye, G Douce, J Andrews, R Wise. Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers. Antimicrobial agents and chemotherapy. 1990 Feb; 34(2):232-4. doi: 10.1128/aac.34.2.232. [PMID: 2327771]
  • G S Hughes, D L Heald, K B Barker, R K Patel, C R Spillers, K C Watts, D H Batts, A R Euler. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clinical pharmacology and therapeutics. 1989 Dec; 46(6):674-85. doi: 10.1038/clpt.1989.204. [PMID: 2557183]
  • H Kimura, H Takeuchi, H Ishikawa, F Hayakawa, N Yamamoto, Y Nakao, K Kuno. [Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. The Japanese journal of antibiotics. 1989 Jul; 42(7):1593-606. doi: . [PMID: 2562789]
  • T Motohiro, K Oda, M Aramaki, A Kawakami, K Tanaka, T Koga, Y Sakata, T Fujimoto, K Yokochi, F Yamashita. [Pharmacokinetic and clinical studies on cefpodoxime proxetil dry syrup in the field of pediatrics]. The Japanese journal of antibiotics. 1989 Jul; 42(7):1629-66. doi: . [PMID: 2681864]
  • Y Toyonaga, M Koizumi, H Imai, M Sugita, T Takahashi, Y Fukushima, M Yamasaki, M Hori. [Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. The Japanese journal of antibiotics. 1989 Jul; 42(7):1519-46. doi: . [PMID: 2810728]
  • K Niino, H Sato, A Narita, S Nakazawa, H Suzuki, K Matsumoto, S Nakazawa. [Evaluation of cefpodoxime proxetil in the pediatric field]. The Japanese journal of antibiotics. 1989 Jul; 42(7):1505-18. doi: NULL. [PMID: 2810727]
  • T Yokota, E Suzuki, K Arai. Cefpodoxime proxetil, its in vitro antibacterial activity, affinity to bacterial penicillin-binding proteins, and synergy of bactericidal activity with serum complement and mouse-cultured macrophages. Drugs under experimental and clinical research. 1988; 14(8):495-500. doi: . [PMID: 3073932]